1
Prescription Solutions, Irvine, CA, USA, 2 Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA OBJECTIVES: To determine if switching from select branded to generic equivalent antiepileptic drug (AED) in patients with epilepsy is associated with adverse outcomes or with utilization changes that may proxy for adverse outcomes. METHODS: A retrospective cohort study using a large health insurance plan claims database was undertaken comparing patients with ICD-9-CM codes of epilepsy or non-febrile convulsions who switched from brand to generic equivalent AED after 6 months (switch cohort) to those who remained on the brand (non-switch cohort). Potential non-switch subjects were matched 1:1 to 745 phenytoin switch patients, 995 lamotrigine switch patients and 399 divalproex switch patients. Outcomes measured included the event rate ratio (ERR) of the composite of all-cause emergency department (ED) visits or hospitalizations and the incidence rate ratio (IRR) of discontinuation of the index AED, change in dose of index AED or addition of another AED. RESULTS: The switch vs. non-switch cohorts did not demonstrate differences in ED visits or hospitalizations for the studied AEDs (ERR for phenytoin 0.96, 95% CI 0.80-1.16; ERR for lamotrigine 0.97, 95% CI 0.80-1.17; ERR for divalproex 0.83, 95% CI 0.66-1.06). Compared with non-switchers, the phenytoin switch cohort had greater incidence of AED utilization changes (IRR 1.85, 95% CI 1.50-2.29). Lamotrigine and divalproex showed no differences in AED utilization between the switchers and nonswitchers (IRR for lamotrigine 1.00, 95% CI 0.84-1.19; IRR for divalproex 1.02, 95% CI, 0.88-1.42). CONCLUSIONS: Lamotrigine or divalproex brand to generic switching was not associated with increased incidence of ED visits or hospitalizations or utilization changes compared with patients remaining on the branded product. Brand to generic switching of phenytoin was not associated with an increase in ED visits or hospitalizations but was associated with greater numbers of index drug discontinuations, dose changes or therapy augmentations.
PND2 THE VALUE OF A PREDICTIVE DIAGNOSTIC BLOOD TEST IN MULTIPLE SCLEROSIS (MS)
Van Hout BA 1 , Botteman M 2 , Dukler A 3 1 University of Sheffield, Sheffield, UK, 2 Pharmerit North America, LLC, Bethesda, MD, USA, 3 Glycominds Ltd., Lod, Israel OBJECTIVES: To assess the cost effectiveness of gMS®Pro EDSS, a test designed to identify MS patients with a high likelihood of progressing fast and in need of more aggressive treatment. METHODS: A literature-based discrete-event simulation follows patients visiting their physicians at defined EDSS score deteriorations. At each visit, 4 therapies are considered: three less aggressive/less expensive therapies (assumed monthly cost of $2,000/patient) and a more aggressive/more expensive therapy (assumed monthly cost of $3,000/patient) associated with severe side effects. The more agressive therapy is only considered cost effective in fast deteriorating patients. The expected cost effectiveness of each therapy was calculated using a Markov model (using EDSS scores as health states) and applying a Bayesian updating process considering the likelihood that the patient is "fast deteriorating" and/or responds to therapy. The model compares patients' costs and quality of life when the gMS®Pro EDSS test is used vs. when it is not. The estimated sensitivity and specificity of gMS®Pro EDSS were 65.18% and 84.09%, respectively based on clinical trail results. The costs of all non-medication costs were based on Kobelt et al. RESULTS: Using the test, in comparison to not using the test, in a MS population containing 25% of patients who progress fast results in more frequent (25.18% vs. 24.24%) and earlier (2.24 years on average) use of aggressive therapy. The test is estimated to result in a gain of 0.11 QALY's and to be economically dominant up to a price of $2640 (cost of medication is estimated to increase by $2984 which is offset by savings of $2704 of other direct medical costs and $2920 of production losses). CONCLUSIONS: The gMS®Pro EDSS is likely to be a cost effective addition in the identification of the optimal therapy for MS patients. Patients with and without GID were matched by age, gender, comorbidities, and treatment regime. Their respective emerging health outcomes were followed-up for two years. Outcomes were defined on the basis of a literature review and included neuropsychiatric, motor, urogenital disturbances, health care utilization and related costs. RESULTS: In the datacut, GID incidence among patients with PD increased over time to stabilize at 75% at 92 months. 485 patients with PD and GID were matched to 485 controls with PD but without GID. GID was associated with significantly higher rates of neuropsychiatric and motor disorders, including psychosexual dysfunction (RR = 8, p = 0.05), anxiety (RR = 1.61, p < 0.01), depression (RR = 1.28, p = 0.03), ataxia (RR = 1.24, p = 0.03), pain (RR = 1.28, p < 0.01), movement disorders (RR = 1.39, p < 0.01), urinary incontinence (RR = 1.43, p = 0.02), and risk of fall (RR = 1.44, p = 0.04). ER admissions (ratio = 1.42, p < 0.01), number of concurrent drugs (ratio = 1.06, p = 0.04) and PD and non-PD health care costs (ratios = 1.13 and 1.12, p < 0.01 respectively) increased during the observation period in the GID patients. CONCLUSIONS: GID have a substantial deleterious effect on major PDrelated clinical and societal outcomes. Non oral formulations of PD drugs (apomorphine or L-dopa pumps or rotigotine) may offer a good opportunity to bypass gastrointestinal tract, and accordingly maximize patient response to treatment. Database (2005 Database ( -2008 . Patients were continuously enrolled in the 6-month pre-and 6-month post-initiation periods. To control for selection bias, propensity scored matched pregabalin and duloxetine new starts were evaluated. Key study outcomes including imputed medically-related work loss, prescription and health care utilization, and associated expenditures were analyzed using bivariate statistics and multivariate models in a difference-in-difference approach. RESULTS: A total of 946 employees with pDPN (473 per group) were identified. In the pre-index period, there were no statistically significant differences between groups in age (mean 54.0 ± 5.6 pregabalin and 53.3 ± 7.5 duloxetine), gender (females 52% pregabalin, 48% duloxetine), geographic distribution, insurance plan types, comorbidities, medication use, health care resource utilization or health care expenditures. The average number of prescriptions in the 6-month post-index period was 2.9 ± 1.9 for pregabalin and 3.1 ± 2.1 for duloxetine. There were no significant differences between treatment groups for pre-to-post changes in opioid utilization (marginal effect 1.3 percentage points fewer pregabalin opioid patients, p = 0.328) as well as the number of pDPN-related pain medications (marginal effect 0.108 more medications for pregabalin, p = 0.506). The adjusted marginal effects for pre-to-post changes in all-cause health care expenditures ($154 greater increase for pregabalin patients, p = 0.895), pDPN-attributable expenditures ($145 greater increase for pregabalin patients, p = 0.359) and indirect costs ($458 relative decrease for pregabalin patients, p = 0.324) were not statistically significant. CONCLUSIONS: There were no significant pre-to-post differences between pregabalin and duloxetine treatment groups in opioid use, DPN-related pain medication use, pDPN-attributable, all-cause and indirect expenditures.
PND3 GASTROINTESTINAL DISORDERS IN PATIENTS WITH PARKINSON'S DISEASE: A DOUBLE-EDGED SWORD

NEUROLOGICAL DISORDERS -Cost Studies
PND4 ESTIMATED COST SAVINGS WHEN TREATING RESTLESS LEGS SYNDROME (RLS) WITH GABAPENTIN ENACARBIL IN THE US
PND6 MODELING THE ESTIMATED COST-SAVINGS OF STRATIFIED CARE FOR MIGRAINE HEADACHES FROM A U.S. PERSPECTIVE
Furiak N, Bansal M Medical Decision Modeling Inc., Indianapolis, IN, USA OBJECTIVES: To estimate the differences in costs of treating migraine headaches employing a stratified care (STRAT) approach versus the more common stepped care (STEP) using MIDAS scores in the U.S. STRAT using MIDAS scores has been shown to be cost-effective in other settings. However, STRAT is not widely used in the U.S. In this study, a published decision model was adapted to the U.S. setting and the differences in costs were evaluated for STEP and STRAT in the U.S. by differentiating the patients by MIDAS scores. METHODS: Published values for costs of physician/ specialist visits, over the counter (OTC) analgesics, aspirin+metoclopramide (AM), triptans, and hospitalizations were used to create a microsimulation model for a U.S. perspective. Therapy effectiveness for OTCs, AM, and triptans by MIDAS scores I, II, and III were taken from the published decision tree. In the base-case the proportion of MIDAS I, II, and III patients were 5%, 25%, and 70% respectively. STEP patients were forced through each phase of therapy regardless of MIDAS score. STRAT patients were moved ahead to advanced phases of therapy given higher MIDAS score. In the model, a sample of 1000 patients is taken and is distributed according to the MIDAS scores. The costs are attached to each node of the treatment algorithm to obtain the total costs. RESULTS: Base case results showed that mean annual direct medical costs on STEP for the population were $1229 compared to $1088 for STRAT. Sensitivity analysis showed that the differences in costs (STEP-STRAT) were $210 for a cohort of MIDAS II patients and $142 for a cohort of MIDAS III patients. CON-CLUSIONS: Model results indicate that STRAT has the potential for cost savings in a U.S. setting. Increased awareness and used of STRAT can benefit patients, providers, and payers in the treatment of migraine headache.
PND7 THE IMPACT OF SPECIALTY PHARMACY PARTICIPATION ON HEALTH CARE COSTS IN A MULTIPLE SCLEROSIS POPULATION USING BIOLOGIC DMD THERAPY
Faris RJ 1 , Steinberg SC 2 , Bolton C 1 1 Accredo Health, Memphis, TN, USA, 2 Accredo Health and the University of Memphis, Memphis, TN, USA OBJECTIVES: To determine if the pharmacy provider model for patients with relapsing remitting multiple sclerosis (MS) on biologic disease modifying drugs (DMD) impacts medical costs. METHODS: A retrospective cohort study design was used. Pharmacy and medical claims data for MS patients (N = 5,232) were extracted for 2008 from a pharmacy benefit management (PBM) company. The two study populations included: 1) patients who received therapy from a specialty pharmacy, and 2) those who received therapy from retail pharmacies. Adherence was measured using a Medication Possession Ratio (MPR), with patients considered adherent for MPR ≥ 80%. Nonparametric statistical tests and multivariate log-linear regression analyses were used to determine differences between the two populations. RESULTS: The results suggest that MS patients receiving therapy from a specialty pharmacy have significantly lower total medical costs than patients who receive therapy from a retail pharmacy [−0.18; 95% CI −0.33, −0.02]. Overall, specialty pharmacy MS patients tended to have lower total medical costs, IP costs and office visits as compared to retail patients. CONCLUSIONS: DMD therapy is considered an effective treatment for relapsing-remitting MS patients. Specialty pharmacies often have additional patient care services that help the patient manage their therapy more effectively. This study demonstrates that MS patients taking a DMD who are medically managed in a specialty pharmacy setting can achieve lower medical costs. This has significant implications for insurers and patients.
PND8 APPROACH TO MATCHING ALZHEIMER'S DISEASE PATIENTS AND THEIR SPOUSES TO ASSESS CAREGIVER BURDEN IN AN ADMINISTRATIVE CLAIMS DATABASE
University of Utah, Salt Lake City, UT, USA, 2 Milliman, Inc, Denver, CO, USA OBJECTIVES: To present a methodology for matching Alzheimer's disease (AD) patients and their spouses to non-AD couples using an administrative claims database to assess caregiver burden. METHODS: Data were extracted from MarketScan claims databases from January 1, 2002 --December 31, 2008 . Patients with an AD ICD-9 diagnosis code and with a spouse in the database were eligible for matching; their index date was the date of first AD diagnosis. Couples with no AD diagnoses were eligible as controls and were matched 1:1 to AD couples based on patient and spouse birth years ± 3 years, index date ± 1 year (defined as eligibility midpoint), gender, and CDPS risk adjuster score prior to index date. All subjects had continuous eligibility 12+ months pre-and post-index date. RESULTS: Of 12,476 AD patients with spouses who met all inclusion criteria, 12,370 matched to a control couple. AD couples who did not match often had a greater age difference than available control couples. More AD patients and spouses utilized AD medications, antidepressants, anxiolytics, and antipsychotics pre-index date than their controls (p < 0.05). AD patients had a higher pre-index prevalence of non-AD dementia, anxiety, and psychosis than control patients (p < 0.001). AD spouses had increased antidepressant use post index (p < 0.001); control spouses showed no change. AD patients had a greater increase in total costs post index date than control patients (p < 0.001); no difference in total cost was observed between AD and control spouses, whose increases were similar to control patients. CONCLUSIONS: Matching on a risk adjuster score resulted in similar rates of chronic conditions between case and control couples but may have limited the ability to detect whether AD impacts spouse health care resource use. However, significant differences in prevalence of dementia and other mental health conditions were noted for AD patients, and an increase in antidepressant use suggests such a trend.
PND9 HEALTH CARE COSTS STRATIFIED BY EPILEPSY SEVERITY IN A US COMMERCIALLY INSURED SETTING
Richy F 1 , Banerjee S 2 , Makaroff L 2 , Bancel C 3 , Clark C 3 , Gervasoni C 4 , Lilliu H 1 1 UCB Pharma S.A., Brussels, Belgium, 2 Business & Decision, Brussels, Belgium, 3 UCB Pharma Inc., Atlanta, GA, USA, 4 Keyrus nv, Waterloo, Belgium OBJECTIVES: To measure health care costs related to epilepsy severity using real-life claims data (Pharmetrics®, IMS, USA) in a representative sample from a U.S. commercially-insured population. METHODS: The observation period ranged from January 2006-December 2007. Patients with at least two diagnoses of epilepsy before the observation period and at least two claims for anti-epileptic drugs (AEDs) during the observation period were included. As Pharmetrics® does not report data on disease severity, the number of epilepsy-related emergency room visits over two years (0, 1, 2, ≥3) was used as a proxy. Covariates included age, gender, region, epilepsy-type, number of co-morbidities, concomitant AEDs, and treatment duration. Annualized costs were split into AED medications and non-AED costs. Non-AED costs included non-AED medications and 'other' costs including emergency room visits, hospitalizations, and physician visits. RESULTS: A total fo 9163 patients were included, with 14% in the most severe category (≥3 ER visits). Total annualized costs ranged from US$6,000 to $33,000 depending on disease severity. AED costs were not linked to severity; however 'other costs' increased disproportionately with disease severity. In the unadjusted analysis, mean annualized AED, non-AED medication and 'other' costs were $2,513, $1,276 and $2,522, respectively, for those with no ER visits and $3,279, $3,457 and $26,270, respectively, for those with ≥3 ER visits. The rise in 'other' costs with severity was mainly attributable to hospitalization costs. In the adjusted analysis, the difference between AED and 'other' costs increased significantly with epilepsy severity, number of co-morbidities, and age, whereas it decreased with improved AED compliance. CONCLUSIONS: Non-AED treatment costs increased disproportionately with epilepsy severity, driven mainly by hospitalization. AED medication costs were not related to disease severity. This analysis suggests cost savings may be achieved through targeted strategies and improvement of patient compliance in cases of severe epilepsy.
